Management of neuronopathic Gaucher disease: Revised recommendations

Journal of Inherited Metabolic Disease

Volumn 32, Issue 5, 2009, Pages 660-664

  Vellodi, A ^a   Tylki Szymanska, A ^b   Davies, E H ^c   Kolodny, E ^d   Bembi, B ^e   Collin Histed, T ^f   Mengel, E ^g   Erikson, A ^h   Schiffmann, R ⁱ  

^a Metabolic Unit   (United Kingdom)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Ospedale Universitario   (Italy)

^f Gauchers Association Ltd   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h UMEÅ UNIVERSITY   (Sweden)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME;

ARTICLE; DISEASE CLASSIFICATION; DRUG MEGADOSE; ENZYME REPLACEMENT; FAMILY COUNSELING; GAUCHER DISEASE; HUMAN; NEURONOPATHIC GAUCHER DISEASE; NEUROPATHIC GAUCHER DISEASE; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; SPLENECTOMY;

COUNSELING; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; HEALTH PLANNING GUIDELINES; HUMANS; SOCIAL SUPPORT;

EID: 70350304844     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1164-2     Document Type: Article

References (25)

1. Abrahamov A, Elstein D, Gross-Tsur V, et al (1995) Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet 346: 1000-1003
2. Altarescu G, Hill S, Wiggs E, Jeffries N, et al (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 138: 539-547
3. Beutler E, Grabowski G A (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635-3638
4. Bove KE, Daugherty C, Grabowski GA (1995) Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol 26: 1040-1045
5. Czartoryska B, Tylki-Szymanska A, Lugowska A (2000) Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 33: 147-149 147-149
6. Davies EH, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A (2007a) Outcome of type III Gaucher disease on enzyme replacement therapy: Review of 55 cases. J Inherit Metab Dis 30: 935-942
7. Davies EH, Surtees R, DeVile C, Schoon I, Vellodi A (2007b) A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 30: 768-782
8. Elstein D, Abrahamov A, Zimran A (1998) Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. Clin Genet 54: 179-184
9. Erikson A (1986) Gaucher disease - Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl 326: 1-42
10. Erikson A, Johansson K, Mansson JE, Svennerholm L (1993) Enzyme replacement therapy of infantile Gaucher disease. Neuropediatrics 24: 237-238
11. Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE (2006) Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr 95: 312-317.
12. Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E (2003) Phenotypic continuum in neuronopathic Gaucher disease: An intermediate phenotype between type 2 and type 3. J Pediatr 143: 273-276
13. Goker-Alpan O, Wiggs EA, Eblan MJ, et al (2008) Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease. J Pediatr 153: 89-94
14. Harris CM, Taylor DS, Vellodi A (1999) Ocular motor abnormalities in Gaucher disease. Neuropediatrics 30: 289-293
15. Inui K, Yanagihara K, Otani K, et al (2001) A new variant neuropathic type of Gaucher's disease characterized by hydrocephalus, corneal opacities, deformed toes, and fibrous thickening of spleen and liver capsules. J Pediatr 138: 137-139
16. Krasnewich D, Dietrich K, Bauer L, Ginns EI, Sidransky E, Hill S (1998) Splenectomy in Gaucher disease: New management dilemmas. Blood 91: 3085-3087
17. Kyllerman M, Conradi N, Mansson JE, Percy AK, Svennerholm L (1990) Rapidly progressive type III Gaucher disease: Deterioration following partial splenectomy. Acta Paediatr Scand. 79: 448-453
18. Maas M, Hangartner T, Mariani G, et al (2008) Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skeletal Radiol. 37: 185-188
19. Pastores GM, Weinreb NJ, Aerts H, et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41: 4-14
20. Prows CA, Sanchez N, Daugherty C, Grabowski GA (1997) Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 71: 16-21
21. Shiihara T, Oka A, Suzaki I, Ida H, Takeshita K (2000) Communicating hydrocephalus in a patient with Gaucher's disease type 3. Pediatr Neurol 22: 234-236
22. Tylki-Szymanska A, Czartoryska B (1999) Enzyme replacement therapy in type III Gaucher disease. J Inherit Metab Dis 22: 203-204
23. Tylki-Szymanska A, Keddache M, Grabowski GA (2006) Characterization of neuronopathic Gaucher disease among ethnic Poles. Genet Med 8: 8-15
24. Uchiyama A, Tomatsu S, Kondo N, et al (1994) New Gaucher disease mutations in exon 10: A novel L444R mutation produces a new NciI site the same as L444P. Hum Mol Genet 3: 1183-1184
25. Vellodi A, Bembi B, de Villemeur TB, et al; Neuronopathic Gaucher Disease Task Force (2001) Management of neuronopathic Gaucher disease: A European consensus. J Inherit Metab Dis 24: 319-327